Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | ACP1 | P24666 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212987 | 0.90 | ALDH1A1 (0.68) | RIPK1NPC1RAB9AALDH1A1AHR | |
| SCHEMBL5213188 | 0.82 | NOS3 (0.48) | RIPK1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL5310554 | 0.81 | RIPK1 (0.73) | RIPK1NPC1RAB9AALDH1A1ACP1 | |
| SCHEMBL5212896 | 0.80 | RIPK1 (0.60) | RIPK1NPC1RAB9AAPOBEC3AAPOBEC3G | |
| SCHEMBL11204735 | 0.78 | RIPK1 (0.93) | RIPK1NPC1RAB9AALDH1A1ACP1 | |
| SCHEMBL5212426 | 0.78 | RIPK1 (0.76) | RIPK1NPC1RAB9AALDH1A1ACP1 | |
| SCHEMBL5005629 | 0.78 | RIPK1 (0.72) | RIPK1NPC1RAB9AALDH1A1ACP1 | |
| SCHEMBL5005571 | 0.78 | RIPK1 (0.72) | RIPK1NPC1RAB9AALDH1A1ACP1 | |
| SCHEMBL31730084 | 0.78 | RIPK1 (0.76) | RIPK1NPC1RAB9AALDH1A1ACP1 | |
| SCHEMBL5001727 | 0.77 | RIPK1 (0.67) | RIPK1NPC1RAB9AALDH1A1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539724-B1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-7141595-B2 | Amino benzothiazole compounds with NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | NEURAXON INC. (CA) | 2005-09-22 | — | — | US | disclosed |
| EP-1539724-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014885-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | GAP43, NLN, TRPV1 | RIPK1 3620/4885NPC1 689/4885RAB9A 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.